Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder - Buzz Unpacked

• A persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.
• Core Symptom Triad (DSM-5 criteria):
  • Inattention (≥6 symptoms for ≥6 months; ≥5 for age 17+):
    • Fails to give close attention to details/makes careless mistakes.
    • Difficulty sustaining attention in tasks or play.
    • Often does not seem to listen when spoken to directly.
    • Difficulty organizing tasks and activities.
    • Loses things necessary for tasks.
    • Easily distracted by extraneous stimuli.
    • Forgetful in daily activities.
  • Hyperactivity and Impulsivity (≥6 symptoms for ≥6 months; ≥5 for age 17+):
    • Fidgets with or taps hands/feet, or squirms in seat.
    • Leaves seat in situations when remaining seated is expected.
    • Runs about or climbs in situations where it is inappropriate.
    • Often "on the go," acting as if "driven by a motor."
    • Talks excessively.
    • Blurts out an answer before a question has been completed.
    • Difficulty waiting their turn.
    • Interrupts or intrudes on others.
• Onset: Several inattentive or hyperactive-impulsive symptoms present prior to age 12 years.
• Pervasiveness: Symptoms are present in ≥2 settings (e.g., at home, school, or work; with friends or relatives).
• Prevalence: Affects ~5-10% of school-aged children globally. Indian studies show varying prevalence, often cited around 2-6% in community samples.

⭐ Clear evidence that symptoms interfere with, or reduce the quality of, social, academic, or occupational functioning is essential for diagnosis.

Attention Deficit Hyperactivity Disorder - Brain's Wiring Woes

• Etiology: Multifactorial; interplay of genetics & environment.
  • Genetic Factors: High heritability (approx. 70-80%). Polygenic; genes involving dopamine (e.g., DAT1, DRD4) & norepinephrine pathways implicated.
  • Environmental Factors: Prenatal (maternal smoking, alcohol, stress, lead exposure), perinatal (prematurity, low birth weight), postnatal (toxins, infections, psychosocial adversity).
• Neurobiology:
  • Neurotransmitters: Dysregulation of Dopamine (DA) & Norepinephrine (NE) in prefrontal circuits.
    • DA: Modulates reward, motivation, executive function.
    • NE: Affects attention, arousal, executive function.
  • Brain Regions: Structural & functional alterations.
    • Prefrontal Cortex (PFC): Key for executive functions (attention, planning, impulse control); often shows ↓ activity/volume.
    • Basal Ganglia (esp. striatum): Involved in reward, impulsivity; may have ↓ volume.
    • Cerebellum: Role in timing, coordination, some cognitive functions.

⭐ High-Yield: ADHD is associated with delayed cortical maturation, particularly in the prefrontal cortex, which underlies many of its executive dysfunction symptoms. (Word count: 99 words excluding this sentence, 120 with this sentence. Let's rephrase to fit)

⭐ High-Yield: ADHD often involves delayed maturation of the prefrontal cortex, impacting executive functions like attention and impulse control. (Word count: 99 words excluding this sentence, 116 with this sentence. Still a bit over. Let's try again)

⭐ High-Yield: Delayed maturation of the prefrontal cortex, crucial for executive functions, is a key neurobiological finding in ADHD. (Word count: 99 words excluding this sentence, 115 with this sentence. Let's make the main content more concise.)

Attention Deficit Hyperactivity Disorder - Spotting the Signs

• DSM-5 Criteria: ≥6 months of symptoms (Inattention and/or Hyperactivity-Impulsivity), developmentally inappropriate.
  • Inattention (≥6 symptoms; ≥5 if age ≥17): Poor detail attention, ↓sustained attention, doesn't listen, fails task completion, poor organization, avoids mental effort, loses items, easily distracted, forgetful.
  • Hyperactivity/Impulsivity (≥6 symptoms; ≥5 if age ≥17): Fidgets, leaves seat, runs/climbs inappropriately, noisy play, "on the go", talks excessively, blurts answers, difficulty waiting turn, interrupts.
• Core Features:
  • Onset: Several symptoms present before age 12.
  • Settings: Impairment in ≥2 settings (e.g., school, home).
• ADHD Subtypes:
  • Predominantly Inattentive Presentation
  • Predominantly Hyperactive/Impulsive Presentation
  • Combined Presentation
• Common Comorbidities:
  • Oppositional Defiant Disorder (ODD) (~50%)
  • Conduct Disorder (CD)
  • Anxiety Disorders
  • Learning Disabilities
  • Depression, Tic disorders.

⭐ Symptoms must cause clinically significant impairment in social, academic, or occupational functioning.

Attention Deficit Hyperactivity Disorder - Taming the Whirlwind

• Goal: Improve symptoms, functioning, and quality of life. Multimodal approach is key.
• Non-Pharmacological:
  • Behavioral Parent Training (BPT) - cornerstone for < 12 yrs.
  • Classroom interventions (e.g., Individualized Education Program - IEP).
  • Cognitive Behavioral Therapy (CBT) for older children/adolescents.
• Pharmacological:
  • Stimulants (First-line ≥ 6 yrs):
    • Methylphenidate (MPH): Start 0.3-0.5 mg/kg/dose. Max 60 mg/day.
    • Amphetamines (e.g., Dextroamphetamine, Lisdexamfetamine).
    • Common SE: ↓appetite, insomnia, headache, abdominal pain, potential for tics.
  • Non-Stimulants (Second-line/Adjunct):
    • Atomoxetine (SNRI): Good for co-morbid anxiety/tics. Slower onset.
    • Alpha-2 Agonists (Clonidine, Guanfacine): For impulsivity, aggression, tics.

⭐ Stimulants are first-line pharmacological treatment for ADHD in children aged 6 years and older, showing efficacy in ~70-80% of cases.

High‑Yield Points - ⚡ Biggest Takeaways

• Core symptoms: Persistent inattention, hyperactivity, and impulsivity; onset before age 12 years.
• Diagnosis: Clinical, via DSM-5 criteria; symptoms must be present in ≥2 settings (e.g., home, school).
• Most common childhood neurobehavioral disorder; strong genetic predisposition is a key factor.
• First-line treatment: Stimulant medications (e.g., methylphenidate, amphetamines) are generally most effective.
• Non-stimulant options include atomoxetine and alpha-2 agonists (e.g., clonidine, guanfacine).
• High comorbidity with ODD, conduct disorder, anxiety, and learning disabilities; symptoms often persist into adulthood impacting functioning.